Peter Boockvar, CIO at One Point BFG Wealth Partners, says earnings will likely beat expectations, but tariffs, freight weakness, and uneven consumer spending reveal a split U.S. economy.

Jason Bazinet, Media & Entertainment Analyst at Citigroup, says Netflix's rally stems from investors seeking safety and streaming growth, but its market share has stayed flat despite strong content.

NEM, RY, AS, VSTM and SOTK have been added to the Zacks Rank #1 (Strong Buy) List on Oct. 21, 2025.

The chip maker's shares were edging down as more details about its business arrangements with the ChatGPT-developer emerged.

Taiwan Semiconductor Manufacturing Company Ltd (NYSE:TSM) is gaining momentum as the artificial intelligence frenzy from tech giants drive unprecedented growth.

Shares of cryptocurrency exchange Gemini Space Station (NASDAQ: GEMI) have experienced a tumultuous beginning following their highly awaited debut last month. The company set its IPO price at $28 per share, raising several hundred million dollars in the process.

Amazon.com (AMZN) has faced challenges previously. Its stock has dropped by more than 30% within a period of less than 2 months on three separate occasions in various years, erasing billions in market capitalization and eliminating substantial gains in a single correction.

Subsidiary expected to pursue DoD and DHS contracts with focus on non-lethal BolaWrap® 150 devices, DFR-X drone interdiction technology, and CUAS programs to enhance mission safety and operational readiness Subsidiary expected to pursue DoD and DHS contracts with focus on non-lethal BolaWrap® 150 devices, DFR-X drone interdiction technology, and CUAS programs to enhance mission safety and operational readiness

PHILADELPHIA and VANCOUVER, British Columbia, Oct. 21, 2025 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW, BCTXZ), (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care, is pleased to announce a collaboration with Memorial Sloan Kettering Cancer Center's (MSK's) Therapeutics Accelerator Cohort program to accelerate the clinical development of Bria-OTS+, BriaCell's next generation personalized off-the-shelf immunotherapy, for multiple cancer indications including metastatic breast cancer, prostate cancer, and other cancers.

Schwab U.S. Dividend Equity ETF™ and PepsiCo, Inc. are positioned to benefit as market enthusiasm for AI normalizes and investors seek reliable dividend payers. SCHD offers a 3.86% yield, low expense ratio, and potential for capital appreciation as interest rates fall and fixed-income yields decline. PEP faces near-term headwinds but boasts strong liquidity, strategic acquisitions, and a below-average valuation, supporting long-term upside.

Winnipeg, Manitoba--(Newsfile Corp. - October 21, 2025) - Snow Lake Resources Ltd., d/b/a Snow Lake Energy (NASDAQ: LITM) ("Snow Lake"), a uranium exploration and development company, announces a major strategic expansion with the creation of Kadmos Energy Services LLC ("Kadmos"), a new U.S. based nuclear energy company dedicated to the design and deployment of small modular reactors ("SMRs"), with an initial focus on light water reactors.

Antero Resources is my largest, highest-conviction trade, driven by bullish long-term fundamentals for natural gas and favorable industry positioning. AR stands out for its ultra-low-cost reserves, superior pricing, strong balance sheet, and significant exposure to LNG exports and AI/data center demand. I rate AR a Strong Buy, expecting potential upside of 40% to 200%+ if natural gas prices normalize and industry trends play out as anticipated.

Wolfspeed emerges from bankruptcy with a restructured balance sheet, slashing debt by 70% and extending maturities to 2030. WOLF's new manufacturing capacity and reduced capex position it for growth, but diluted share count complexities and incentive plans add uncertainty to valuation. The stock trades at just 2x sales, with long-term targets forecasting 15%-20% annual sales growth and solid EBITDA gains.

RENO, Nev., Oct. 21, 2025 (GLOBE NEWSWIRE) -- Dragonfly Energy Holdings Corp. (“Dragonfly Energy” or the “Company”) (Nasdaq: DFLI), an industry leader in energy storage and battery technology, today announced that it has received a letter (the “Letter”) on October 20, 2025 from the Nasdaq Hearings Panel of the Nasdaq Stock Market LLC (“Nasdaq”) stating that the Company regained compliance with both the minimum bid price requirement in Listing Rule 5550(a)(2) (the “Minimum Bid Price Requirement”) and the minimum market value of listed securities requirement in Listing Rule 5550(b)(2) for continued listing on the Nasdaq Capital Market. Accordingly, the Company …

VANCOUVER, British Columbia, Oct. 21, 2025 (GLOBE NEWSWIRE) -- ZenaTech, Inc. (Nasdaq: ZENA) (FSE: 49Q) (BMV: ZENA) ("ZenaTech"), a business technology solution provider specializing in AI (Artificial Intelligence) drones, Drone as a Service (DaaS), Enterprise SaaS, and Quantum Computing solutions, today announces it has signed an offer to acquire a Southern California land survey engineering firm with a considerable list of long-term government and commercial builder customers and significant expertise in public works projects. The acquisition would expand ZenaTech's DaaS presence in Southern California, providing opportunities to modernize and improve a range of surveying, inspection, and monitoring applications for government …

Expands commercial readiness and diagnostic, manufacturing footprint Appoints new leadership in commercial strategy and technical operations HOUSTON, Oct. 21, 2025 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system (CNS) cancers, announces continued operational execution and commercial progress in the launch of its wholly owned subsidiary, CNSide Diagnostic LLC's, Cerebrospinal Fluid (CSF) Tumor Cell Enumeration laboratory developed test (LDT). Recent accomplishments include expansion of the CNSide manufacturing footprint, advancements in commercial readiness and appointments in key leadership positions to propel the CNSide diagnostic business …

This news release constitutes a “designated news release” for the purposes of the Company's prospectus supplement dated May 30, 2025 to its short form base shelf prospectus dated May 15, 2025 This news release constitutes a “designated news release” for the purposes of the Company's prospectus supplement dated May 30, 2025 to its short form base shelf prospectus dated May 15, 2025

DALLAS, Oct. 21, 2025 (GLOBE NEWSWIRE) -- Beneficient (NASDAQ: BENF) (“Ben” or the “Company”), a technology-enabled platform providing exit opportunities and primary capital solutions and related trust and custody services to holders of alternative assets through its proprietary online platform, AltAccess, today reported its financial results for the fiscal 2026 first quarter, which ended June 30, 2025. Commenting on the fiscal 2026 first quarter results, interim Chief Executive Officer James Silk said: “This quarter reflects meaningful progress strengthening Beneficient's financial and operational foundation.

Unifying global IP rights and enabling up to $5 million in potential shareholder contributions, the agreement strengthens Telomir's foundation for partnerships, licensing, and long-term value creation. MIAMI, FLORIDA / ACCESS Newswire / October 21, 2025 / Telomir Pharmaceuticals, Inc. (NASDAQ:TELO) ("Telomir" or the "Company"), a preclinical-stage biotechnology company developing therapies that target epigenetic drivers of cancer, aging, and age-related disease, today announced that it has executed a binding Letter of Intent (the "LOI") to acquire TELI Pharmaceuticals, Inc., securing worldwide rights to its lead investigational therapy, Telomir-1.

NEW YORK--(BUSINESS WIRE)--Seaport Entertainment Group (NYSE: SEG) announces third quarter 2025 earnings release and conference call information.